



Figure 1. Availability of FDA reviews by year.



**Figure 2. Number of drugs in DERP reports by year of approval.**



**Table 1.** Availability of FDA reviews of drugs included in DERP reports.

Drug class	Number of drugs in class	% with a NDA review available	Range of approval dates of drugs in class	# of new or modified indications	% of new indications with review available
ACE Inhibitors	11	18% (2/11)	1981–1996	15	27% (4/15)
ADHD drugs	19	58% (11/19)	1960–2007	2	0% (0/2)
Angiotensin 2 receptor antagonists	7	57% (4/7)	1995–2002	7	71% (5/7)
Antidepressants	18	44% (8/18)	1985–2008	20	50% (10/20)
Antiemetics	9	44% (4/9)	1991–2006	10	20% (2/10)
Atypical antipsychotics	12	67% (8/12)	1989–2007	16	38% (6/16)
Beta Blockers	14	14% (2/14)	1967–2006	7	43% (3/7)
Combination products for lipid lowering	2	100% (2/2)	2001–2004	0	NA
Insomnia Drugs	5	100% (5/5)	1992–2005	1	0% (0/1)
Overactive bladder drugs	10	70% (7/10)	1970–2007	0	NA
Peginterferons for hepatitis C infection	2	100% (2/2)	2001–2002	0	NA
Proton Pump inhibitors	6	67% (4/6)	1989–2003	14	21% (3/14)
Stains	7	29% (2/7)	1987–2000	25	44% (11/25)
Thiazolidinediones	2	100% (2/2)	1999	3	67% (2/3)
Triptans	12	67% (8/12)	1992–2003	1	0% (0/1)
<b>TOTALS</b>	<b>136</b>	<b>52% (71/136)</b>	<b>1960–2008</b>	<b>121</b>	<b>38% (46/121)</b>